$ZLDPF

Zealand Pharma is seeking partners for its rare-disease drug glepaglutide, which treats short bowel syndrome, as it focuses on obesity treatments. The company resumed talks after a positive EU regulatory recommendation. A final EU decision on glepaglutide is expected in Q4, while a new US trial is underway. Zealand is also in discussions for dasiglucagon, a treatment for low blood sugar, with a US resubmission expected this quarter.

Zealand Pharma (CSE:ZELA) reported a 70% increase in Q3 underlying loss to 685M DKK due to rising obesity drug R&D costs, with revenue dropping to 4M DKK. A one-off gain from royalty rights sale reduced net loss to 54M DKK. The company narrowed its 2026 operating cost forecast but kept revenue guidance at 4.5B DKK. Phase 2 trials for petrelintide showed promising weight loss and blood sugar reduction results.

Zealand Pharma reported Q3 2026 financials: revenue DKK 9.1B, net profit DKK 6.8B. Key updates: Phase 3 trial initiation for petrelintide, positive CHMP opinion for Zeydovio, and new research hub in Cambridge. Boehringer Ingelheim's survodutide showed promising results in obesity and type 2 diabetes trials.

Zealand Pharma's survodutide met the primary endpoint in a Phase 3 trial, showing no increased cardiovascular risk. The company plans to proceed with global regulatory submissions for obesity treatment. Boehringer Ingelheim conducted the trial.

Zealand Pharma (ZEAL.CO) reported positive Phase 1 trial results for ZP9830, an investigational Kv1.3 ion channel blocker. The trial showed favorable tolerability with no serious adverse events. The company plans further trials in plaque psoriasis and another autoimmune disease. ZEAL.CO shares are trading at DKK 221.50, down 2.12%.

Zealand Pharma (ZEAL) partnered with Generate Biomedicines to develop AI-designed protein therapeutics for obesity and metabolic diseases. Generate receives $30M upfront, up to $35M in early milestones, and potential $1.2B in total milestones plus royalties. The collaboration expands Zealand's focus into AI-designed proteins.

Zealand Pharma reported positive Phase 2 results for petrelintide, showing 9.2% mean weight loss vs 2.0% placebo and HbA1c reductions of 0.61%-0.88%. No unexpected safety issues were noted. The company is moving into Phase 3 trials with Roche.

Zealand Pharma A/S (ZEAL) completed a share buyback program, repurchasing 4.4 million shares for DKK 1.3 billion at an average price of DKK 294.88. The company now holds 5.3 million treasury shares, representing 7.37% of its share capital, according to the company.

Zealand Pharma (ZEAL) opened a new research hub in Cambridge, Massachusetts, expanding its metabolic health research capabilities. The company aims to become a leader in obesity and metabolic health, with the new hub focusing on hybrid modalities and advanced modeling techniques. Zealand Pharma is actively hiring and expects continued growth at the site.

Zealand Pharma's stock fell 11.7% after its partner Boehringer Ingelheim released Phase III trial results for survodutide. The drug met its primary endpoints, but 18% of patients discontinued due to gastrointestinal side effects. Investors are concerned about the drug's differentiation in the competitive obesity market, impacting Zealand's future revenues.